romidepsin
not tagged
['ptcl', 'lymsm']
final 5-yr ro-chop rct #17icml
- no diff in survival between arms (altho pfs sig higher in ro arm with ptcl-tfh)
- chop delivery compromised by romi
- subsequent os bad (11.5 mos)
- bv in 2nd line with better pfs/os (cd30 unknown)
romi potentially an option in tfh subtype? #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈